Breed · Dog

Shiba Inu: adverse event reports

FDA breed label "Shiba Inu" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

1,675reports, 2000–20260.2% of dog reports

109reports, 12 months to March 2026103 in the 12 months before

37.5%classed serious, as reportedall dogs: 38.3%

16.7%name milbemycin oxime + spinosadall dogs: 13.1%

1,675 adverse event reports received by FDA describe an animal recorded as Shiba Inu (FDA breed label "Shiba Inu"). That is 0.2% of all reports about dogs. Crossbred animals are not counted here, only reports that give this single breed.

109 reports arrived in the 12 months to March 2026, close to the 103 of the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, ivermectin + pyrantel pamoate and fluralaner. Milbemycin Oxime + Spinosad is named in 16.7% of this breed's reports, a larger share than in reports about all dogs (13.1%).

The terms listed most often are vomiting (21.5%), lethargy (12.5%) and diarrhoea (8.6%). Vomiting appears in 21.5% of reports, about the same share as in all dog reports (19.7%). 37.5% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Shiba Inu reports	Share of all dog reports
Milbemycin Oxime + Spinosad	280	16.7%	13.1%
Ivermectin + Pyrantel Pamoate	181	10.8%	14.9%
Fluralaner	138	8.2%	6.7%
Afoxolaner	131	7.8%	5.7%
Pyrantel Pamoate + Sarolaner	123	7.3%	5.1%
Oclacitinib	105	6.3%	2.9%
Spinosad	88	5.3%	5.8%
Cyclosporine	81	4.8%	1.5%
Moxidectin	61	3.6%	5%
Milbemycin Oxime + Praziquantel	51	3%	3.1%
Lufenuron + Milbemycin Oxime	47	2.8%	2.7%
Bedinvetmab	44	2.6%	1.9%
Carprofen	37	2.2%	4.8%
Selamectin	33	2%	3%
Sarolaner	32	1.9%	1.7%
Milbemycin Oxime	30	1.8%	3%
Florfenicol + Mometasone furoate + Terbinafine	25	1.5%	0.3%
Maropitant	25	1.5%	1.2%
Grapiprant	19	1.1%	0.8%
Butorphanol Tartrate	18	1.1%	0.4%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Shiba Inu reports listing the termall dog reports

Vomiting21.5%360
Lethargy[unusually tired or inactive]12.5%210
Diarrhoea[diarrhea]8.6%144
Emesis[vomiting]6.4%107
Seizure NOS[seizure, type not specified]6%101
Anorexia[not eating]5.6%93
Behavioural disorder NOS[behaviour change, type not specified]4.4%73
Lack of efficacy - NOS[the product did not have the expected effect]4.4%73
Ataxia[unsteady, uncoordinated movement]4.1%68
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]4%67
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]3.9%66
Depression[dull, quiet or withdrawn]3.6%60
Shaking2.9%49
Panting2.9%48
Pruritus[itching]2.7%45
Trembling2.3%38
Itching2.1%35
Decreased appetite2%34
Lack of efficacy (bacteria) - Borrelia[the product did not have the expected effect: Borrelia (Lyme disease bacteria)]2%33
Ineffective, ascarids NOS[legacy FDA term: the product did not have the expected effect (ascarids nos)]1.9%32
Other abnormal test result NOS[abnormal laboratory result, type not specified]1.9%32
Digestive tract disorder NOS[digestive problem, type not specified]1.8%30
Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]1.8%30
Emesis (multiple)[vomiting more than once]1.7%29
Vocalisation[crying out or unusual noise]1.7%29

Age and weight

Age of the animal

Under 1 year13.1%219

1 to 3 years33%553

4 to 7 years22.4%375

8 to 11 years16.7%279

12 years and over13.3%223

Age not given1.6%26

Weight of the animal

Under 5 kg (11 lb)3.6%61

5 to 9.9 kg (11–22 lb)32.1%538

10 to 24.9 kg (22–55 lb)60.5%1,013

25 to 44.9 kg (55–99 lb)0.9%15

45 kg and over (99 lb+)0%0

Weight not given2.9%48

Coloured bar: Shiba Inu reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal32.6%546

Recovered with Sequela2.1%36

Ongoing23.3%390

Died1.7%28

Euthanized1.2%20

Outcome Unknown24.7%413

Beside all dogs

Measure	Shiba Inu	All dogs
Reports	1,675	985,675
Latest 12 months	109	53,292
Classed serious, of reports stating it	37.5%	38.3%
Death or euthanasia recorded, per 1,000 reports	28.7	55

Questions about Shiba Inu reports

How many FDA adverse event reports involve Shiba Inus?

1,675 reports through March 2026, 0.2% of reports about dogs; 109 in the latest 12 months.

Which drugs are named most often in Shiba Inu reports?

By active ingredient: milbemycin oxime + spinosad (280), ivermectin + pyrantel pamoate (181), fluralaner (138), afoxolaner (131) and pyrantel pamoate + sarolaner (123). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (21.5%), lethargy (12.5%), diarrhoea (8.6%), emesis (6.4%) and seizure NOS (6%).

Is the Shiba Inu more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Shiba Inu animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Shiba Inu" becomes "Shiba Inu"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.